NURIX THERAPEUTICS, INC.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $342.3M | $80.5M |
| FY2022 | — | $303.7M | $64.5M |
| FY2023 | — | $200.5M | $54.6M |
| FY2024 | — | $527.0M | $110.0M |
| FY2025 | — | $538.7M | $247.0M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $342.3M | $80.5M |
| FY2022 | — | $303.7M | $64.5M |
| FY2023 | — | $200.5M | $54.6M |
| FY2024 | — | $527.0M | $110.0M |
| FY2025 | — | $538.7M | $247.0M |